{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T23:45:18Z","timestamp":1791330318477,"version":"4.3.1"},"reference-count":44,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":1979,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2010,4]]},"DOI":"10.1002\/hep.23485","type":"journal-article","created":{"date-parts":[[2009,12,4]],"date-time":"2009-12-04T10:19:13Z","timestamp":1259921953000},"page":"1274-1283","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":395,"title":["A meta\u2010analysis of survival rates of untreated patients in randomized clinical trials of hepatocellular carcinoma\u2020"],"prefix":"10.1097","volume":"51","author":[{"given":"Giuseppe","family":"Cabibbo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Enea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Attanasio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordi","family":"Bruix","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Crax\u00ec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Calogero","family":"Camm\u00e0","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-24-20250312","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1056\/NEJM199603143341104","article-title":"Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis","volume":"334","author":"Mazzaferro","year":"1996","journal-title":"N Engl J Med"},{"key":"R2-24-20250312","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1055\/s-2007-1007122","article-title":"Prognosis of hepatocellular carcinoma: the BCLC staging classification","volume":"19","author":"Llovet","year":"1999","journal-title":"Semin Liver Dis"},{"key":"R3-24-20250312","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1002\/hep.20933","article-title":"Practice Guidelines Committee, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma","volume":"42","author":"Bruix","year":"2005","journal-title":"HEPATOLOGY"},{"key":"R4-24-20250312","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1093\/jnci\/djn134","article-title":"Design and endpoints of clinical trials in hepatocellular carcinoma","volume":"100","author":"Llovet","year":"2008","journal-title":"J Natl Cancer Inst"},{"key":"R5-24-20250312","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1053\/jhep.2003.50047","article-title":"Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival","volume":"37","author":"Llovet","year":"2003","journal-title":"HEPATOLOGY"},{"key":"R6-24-20250312","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/S0140-6736(09)60381-0","article-title":"Major achievements in hepatocellular carcinoma","volume":"373","author":"Bruix","year":"2009","journal-title":"Lancet"},{"key":"R7-24-20250312","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7326\/0003-4819-151-4-200908180-00135","article-title":"Preferred reporting items for systematic reviews and meta\u2010analyses: the PRISMA statements","volume":"151","author":"Moher","year":"2009","journal-title":"Ann Intern Med"},{"key":"R8-24-20250312","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1002\/1097-0142(19880801)62:3<479::AID-CNCR2820620306>3.0.CO;2-L","article-title":"Doxorubicin versus no antitumor therapy in inoperable hepatocellular carcinoma. A prospective randomized trial","volume":"62","author":"Lai","year":"1988","journal-title":"Cancer"},{"key":"R9-24-20250312","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/0168-8278(90)90110-D","article-title":"A randomized trial of hepatic arterial chemoembolization in patients with unresectable hepatocellular carcinoma","volume":"11","author":"Pelletier","year":"1990","journal-title":"J Hepatol"},{"key":"R10-24-20250312","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1002\/hep.1840170307","article-title":"Recombinant interferon\u2010alpha in inoperable hepatocellular carcinoma: a randomized controlled trial","volume":"17","author":"Lai","year":"1993","journal-title":"HEPATOLOGY"},{"key":"R11-24-20250312","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1136\/gut.34.11.1598","article-title":"Randomised trial of targeted chemotherapy with lipiodol and 5\u2010epidoxorubicin compared with symptomatic treatment for hepatoma","volume":"34","author":"Madden","year":"1993","journal-title":"Gut"},{"key":"R12-24-20250312","first-page":"66","article-title":"Randomized controlled trial of tamoxifen versus placebo in inoperable hepatocellular carcinoma","volume":"26","author":"Elba","year":"1994","journal-title":"Ital J Gastroenterol"},{"key":"R13-24-20250312","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/S0168-8278(05)80138-2","article-title":"Controlled trial of tamoxifen in patients with advanced hepatocellular carcinoma","volume":"20","author":"Mart\u00ednez Cerezo","year":"1994","journal-title":"J Hepatol"},{"key":"R14-24-20250312","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1056\/NEJM199505113321903","article-title":"A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma.","volume":"332","year":"1995","journal-title":"N Engl J Med"},{"key":"R15-24-20250312","first-page":"1535","article-title":"Treatment of hepatocellular carcinoma with combined suppression and inhibition of sex hormones: a randomized, controlled trial","volume":"21","author":"Manesis","year":"1995","journal-title":"HEPATOLOGY"},{"key":"R16-24-20250312","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/0016-5085(95)90402-6","article-title":"Treatment of hepatocellular carcinoma with tamoxifen: a double\u2010blind placebo\u2010controlled trial in 120 patients","volume":"109","author":"Castells","year":"1995","journal-title":"Gastroenterology"},{"key":"R17-24-20250312","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1200\/JCO.1998.16.2.411","article-title":"Evaluation of antiandrogen therapy in unresectable hepatocellular carcinoma: results of a European Organization for Research and Treatment of Cancer multicentric double\u2010blind trial","volume":"16","author":"Grimaldi","year":"1998","journal-title":"J Clin Oncol"},{"key":"R18-24-20250312","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1136\/gut.42.3.442","article-title":"Treatment of hepatocellular carcinoma with octreotide: a randomised controlled study","volume":"42","author":"Kouroumalis","year":"1998","journal-title":"Gut"},{"key":"R19-24-20250312","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1097\/00004836-199804000-00010","article-title":"Tamoxifen does not improve survival of patients with advanced hepatocellular carcinoma","volume":"26","author":"Riestra","year":"1998","journal-title":"J Clin Gastroenterol"},{"key":"R20-24-20250312","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1002\/hep.510270617","article-title":"Transarterial embolization versus symptomatic treatment in patients with advanced hepatocellular carcinoma: results of a randomized, controlled trial in a single institution","volume":"27","author":"Bruix","year":"1998","journal-title":"HEPATOLOGY"},{"key":"R21-24-20250312","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S0140-6736(98)01259-8","article-title":"Tamoxifen in treatment of hepatocellular carcinoma: a randomised controlled trial.","volume":"352","year":"1998","journal-title":"Lancet"},{"key":"R22-24-20250312","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1002\/(SICI)1097-0142(20000501)88:9<1986::AID-CNCR2>3.0.CO;2-I","article-title":"Combined therapy consisting of intraarterial cisplatin infusion and systemic interferon\u2010alpha for hepatocellular carcinoma patients with major portal vein thrombosis or distant metastasis","volume":"88","author":"Chung","year":"2000","journal-title":"Cancer"},{"key":"R23-24-20250312","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1002\/hep.510310111","article-title":"Randomized controlled trial of interferon treatment for advanced hepatocellular carcinoma","volume":"31","author":"Llovet","year":"2000","journal-title":"HEPATOLOGY"},{"key":"R24-24-20250312","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1111\/j.1572-0241.2000.01688.x","article-title":"Treatment of advanced hepatocellular carcinoma with tamoxifen and the correlation with expression of hormone receptors: a prospective randomized study","volume":"95","author":"Liu","year":"2000","journal-title":"Am J Gastroenterol"},{"key":"R25-24-20250312","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1054\/bjoc.2000.1534","article-title":"Hormonal therapy with megestrol in inoperable hepatocellular carcinoma characterized by variant oestrogen receptors","volume":"84","author":"Villa","year":"2001","journal-title":"Br J Cancer"},{"key":"R26-24-20250312","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1046\/j.1440-1746.2001.02352.x","article-title":"Improved survival with oral administration of enteric\u2010coated tegafur\/uracil for advanced stage IV\u2010A hepatocellular carcinoma","volume":"16","author":"Ishikawa","year":"2001","journal-title":"J Gastroenterol Hepatol"},{"key":"R27-24-20250312","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1053\/jhep.2002.33156","article-title":"Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma","volume":"35","author":"Lo","year":"2002","journal-title":"HEPATOLOGY"},{"key":"R28-24-20250312","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1016\/S0140-6736(02)08649-X","article-title":"Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial","volume":"359","author":"Llovet","year":"2002","journal-title":"Lancet"},{"key":"R29-24-20250312","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1053\/jhep.2002.35071","article-title":"A randomized placebo\u2010controlled study of long\u2010acting octreotide for the treatment of advanced hepatocellular carcinoma","volume":"36","author":"Yuen","year":"2002","journal-title":"HEPATOLOGY"},{"key":"R30-24-20250312","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1053\/jhep.2002.36824","article-title":"High\u2010dose tamoxifen in the treatment of inoperable hepatocellular carcinoma: a multicenter randomized controlled trial","volume":"36","author":"Chow","year":"2002","journal-title":"HEPATOLOGY"},{"key":"R31-24-20250312","doi-asserted-by":"crossref","first-page":"4338","DOI":"10.1200\/JCO.2005.05.470","article-title":"Randomized controlled trial of tamoxifen in advanced hepatocellular carcinoma","volume":"23","author":"Barbare","year":"2005","journal-title":"J Clin Oncol"},{"key":"R32-24-20250312","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1111\/j.1440-1746.2006.04383.x","article-title":"High dose vitamin K3 infusion in advanced hepatocellular carcinoma","volume":"21","author":"Sarin","year":"2006","journal-title":"J Gastroenterol Hepatol"},{"key":"R33-24-20250312","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1002\/hep.21468","article-title":"Long\u2010acting octreotide versus placebo for treatment of advanced HCC: a randomized controlled double\u2010blind study","volume":"45","author":"Becker","year":"2007","journal-title":"HEPATOLOGY"},{"key":"R34-24-20250312","doi-asserted-by":"crossref","first-page":"3164","DOI":"10.3748\/wjg.v13.i23.3164","article-title":"Long acting octreotide in the treatment of advanced hepatocellular cancer and overexpression of somatostatin receptors: randomized placebo\u2010controlled trial","volume":"13","author":"Dimitroulopoulos","year":"2007","journal-title":"World J Gastroenterol"},{"key":"R35-24-20250312","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma","volume":"359","author":"Llovet","year":"2008","journal-title":"N Engl J Med"},{"key":"R36-24-20250312","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1470-2045(08)70285-7","article-title":"Efficacy and safety of sorafenib in patients in the Asia\u2010Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double\u2010blind, placebo\u2010controlled trial","volume":"10","author":"Cheng","year":"2009","journal-title":"Lancet Oncol"},{"key":"R37-24-20250312","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1016\/j.ejca.2009.02.018","article-title":"Treatment of advanced hepatocellular carcinoma with long\u2010acting octreotide: A phase III multicenter, randomised, double blind placebo\u2010controlled study","volume":"45","author":"Barbare","year":"2009","journal-title":"Eur J Cancer"},{"key":"R38-24-20250312","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","article-title":"Assessing the quality of reports of randomized clinical trials: is blinding necessary?","volume":"17","author":"Jadad","year":"1996","journal-title":"Control Clin Trials"},{"key":"R39-24-20250312","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1053\/jhep.2002.31354","article-title":"Endoscopic treatment versus endoscopic plus pharmacologic treatment for acute variceal bleeding: a meta\u2010analysis","volume":"35","author":"Ba\u00f1ares","year":"2002","journal-title":"HEPATOLOGY"},{"key":"R40-24-20250312","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1200\/JCO.2008.19.1973","article-title":"Testing molecular therapies in hepatocellular carcinoma: the need for randomized phase II trials","volume":"27","author":"Llovet","year":"2009","journal-title":"J Clin Oncol"},{"key":"R41-24-20250312","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1111\/j.1365-2036.2008.03692.x","article-title":"Survival of patients with hepatocellular carcinoma in cirrhosis: a comparison of BCLC, CLIP and GRETCH staging systems","volume":"28","author":"Camm\u00e0","year":"2008","journal-title":"Aliment Pharmacol Ther"},{"key":"R42-24-20250312","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1111\/j.1478-3231.2008.01957.x","article-title":"Prognostic indicators in hepatocellular carcinoma: a systematic review of 72 studies","volume":"29","author":"Tandon","year":"2009","journal-title":"Liver Int"},{"key":"R43-24-20250312","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.1016\/S0168-8278(09)60069-6","article-title":"Efficacy and safety of sorafenib in patients with hepatocellular carcinoma (HCC): subanalysis of SHARP trial based on Barcelona Clinic Liver Cancer (BCLC) stage","volume":"50","author":"Bruix","year":"2009","journal-title":"J Hepatol"},{"key":"R44-24-20250312","first-page":"17A","article-title":"Treatment of advanced hepatocellular carcinoma by seocalcitol: an international randomized double\u2010blind placebo\u2010controlled study in 747 patients","volume":"42","author":"Beaugrand","year":"2003","journal-title":"J Hepatol"}],"container-title":["Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhep.23485","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.lww.com\/01515467-201004000-00024","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T07:03:42Z","timestamp":1741763022000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01515467-201004000-00024"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,4]]},"references-count":44,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2010]]}},"URL":"https:\/\/doi.org\/10.1002\/hep.23485","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.2809961.2474079","asserted-by":"object"}]},"ISSN":["0270-9139"],"issn-type":[{"value":"0270-9139","type":"print"}],"subject":[],"published":{"date-parts":[[2010,4]]}}}